# US 8,771,689 B2 · Alpha B-crystallin as a therapy for ischemia or inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,689 B2
- Document ID: US8771689B2
- Status: Granted
- Kind: B2
- Application number: 13/135,079
- Filed: 2011-06-23
- Published: 2011-12-29
- Granted: 2014-07-08
- Earliest claimed: 2006-12-11
- Assignees: The Board of Trustees of the Leland Stanford Junior University; Department of Veterans Affairs
- Applicants: Lawrence Steinman; Shalina Sheryl Ousman; William H. Robinson
- Inventors: Lawrence Steinman; Shalina Sheryl Ousman; William H. Robinson
- Web page: https://patentgrep.com/patent/US8771689B2

## CPC

- A61K 38/1709: {from mammals}
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/75: Agonist effect on antigen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.

## Claims

### Claim 1

A method for inhibiting neuromyelitis optica in a patient, the method comprising:
administering to said patient a therapeutically effective dose of alpha B-crystallin protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent is administered systemically.

### Claim 3 (depends on 2)

The method of claim 2, wherein a route of systemic administration is selected from the group consisting of intraperitoneal, intravenous, intramuscular and subcutaneous administration.

### Claim 4 (depends on 3)

The method of claim 3, wherein administration is intravenous.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient is diagnosed as having neuromyelitis optica prior to the administering step.

### Claim 6 (depends on 1)

The method of claim 1, further comprising:
monitoring the activation of T cells in tissues affected by neuromyelitis optica.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said agent is a fusion polypeptide of αBC and an immunoglobulin Fc polypeptide.